AZNAstraZenecaRunning, no new patients
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
Gastrointestinal Neoplasms · Esophagogastric Junction
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Dec 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 957 (final count)
- Started
- Nov 17, 2020
- Main results expected
- Dec 20, 2024
- Fully finished
- Sep 27, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-free survival (EFS)
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-12-20, no fading
Raw record changes
- none yet
Trial ID NCT04592913 · record last updated 2025-12-24 · checked 2026-11-09 15:47 UTC